ReSearch Pharmaceutical Services (RPS), Inc. Announces Marc Wolff as Chief Financial Officer

FORT WASHINGTON, Pa., July 24, 2013 /PRNewswire/ -- ReSearch Pharmaceutical Services, Inc. (RPS), a next generation CRO that provides comprehensive global Phase 1-4 clinical development solutions to the biopharmaceutical and medical device industries, today announced that Marc Wolff has joined the organization as Chief Financial Officer.

In this role, Marc will direct all financial, tax and treasury aspects of the business including accounting practices, budgeting, financial planning, financing, interface with the financial community, financial analysis, acquisitions and ventures, and monitoring of financial, tax and treasury performance. He joins the company from Catalent Pharma Solutions, where he served in a dual role as Global CFO Softgel Technologies as well as Vice President and General Manager Softgel Businesses in Australia and Japan.

Mr. Wolff has more than fifteen years of CFO experience at public and private global corporations with $50 million to $1.5 billion in revenues, with an established record of success in leading global finance organizations and significantly growing enterprise value.

About RPS
ReSearch Pharmaceutical Services (RPS), the market leading global provider of innovative outsourcing Clinical Development Solutions, provides comprehensive Phase I-IV services to meet the evolving needs of the Biopharmaceutical, Medical Device and Diagnostic industries, customized by customer type (large, mid-size, and small). Built organically, RPS is the fastest growing top 10 global Clinical Research Organization (CRO), with more than 5,000 employees and operations in more than 64 countries with proprietary internal structures. These structures provide both RPS and its partner's greater development flexibility and growth.

For more information about RPS, visit

SOURCE ReSearch Pharmaceutical Services, Inc.